logo
  

FDA Approves Medtronic's Recharge-Free Spinal Cord Stimulation Platform 'Vanta'

The U.S. Food and Drug Administration has approved Medtronic plc's (MDT) Vanta, a high performance recharge-free implantable neurostimulator with a device life that can be optimized up to 11 years.

The Vanta neurostimulator offers nearly twice the device life than competitive primary cell devices. It also utilizes Medtronic's proprietary AdaptiveStim technology for personalized pain relief that adapts to the patient's movement or body position using a built-in accelerometer.

AdaptiveStim technology goes beyond in-office programming by automatically adjusting stimulation to maintain each patient's optimal dose.

The Vanta neurostimulator also provides unmatched full-body MRI access with Medtronic SureScan technology. Approximately 82% of SCS-implanted patients will need at least one MRI within five years of implant.

Medtronic said it is continually innovating to advance spinal cord stimulation therapy technologies that improve quality of life for people with chronic pain. The Vanta neurostimulator represents a 10% increase in longevity compared to PrimeAdvanced, Medtronic's previous generation recharge-free device. It is also 20% smaller than the PrimeAdvanced neurostimulator, with a more rounded, ergonomic contouring to offer enhanced comfort.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The 737 MAX 10, Boeing Co.'s largest 737 Max model, is taking its maiden flight today, reports said citing people familiar with the matter. The flight after months of testing and certification will be around 10 a.m. local time from the Seattle area. The schedule could change depending on weather or other factors. Meanwhile, the jetliner is expected to enter commercial service in 2023. Medical devices supplier Smiths Medical, affiliated to Smiths Group plc, is recalling certain Jelco Hypodermic Needle-Pro Fixed Needle insulin syringes with skewed graduation markings, the U.S. Food and Drug Administration said. The recall was initiated after the company became aware of specific models and lots of Jelco insulin syringes that may exhibit skewed odd number line graduation markings. Saliva-based COVID-19 testing is rolled out as a pilot for public schools in New York City. The new two-month pilot program is being implemented in about 50 New York City public schools and utilizes Fluidigm Technology to offer RT-PCR COVID-19 testing. New York City public schools have instituted mandatory random weekly testing in all reopened school buildings to ensure safer in-person learning.
Follow RTT